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Stephania A. Cormier,a Bishwas Shrestha,a Jordy Saravia,a Greg I. Lee,a Li Shen,b John P. DeVincenzo,a,c Young-in Kim,a Dahui Youa
Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USAa; College of Medicine, Hunan Normal University, Changsha, Hunan,
People’s Republic of Chinab; Le Bonheur Children’s Hospital, Memphis, Tennessee, USAc
ABSTRACT
Respiratory syncytial virus (RSV) infection is the number one cause of bronchiolitis in infants, yet no vaccines are available be-
cause of a lack of knowledge of the infant immune system. Using a neonatal mouse model, we previously revealed that mice ini-
tially infected with RSV as neonates develop Th2-biased immunopathophysiologies during reinfection, and we demonstrated a
role for enhanced interleukin-4 receptor  (IL-4R) expression on T helper cells in these responses. Here we show that RSV in-
fection in neonates induced limited type I interferon (IFN) and plasmacytoid dendritic cell (pDC) responses. IFN alpha (IFN-)
treatment or adoptive transfer of adult pDCs capable of inducing IFN- prior to neonatal RSV infection decreased Th2-biased
immunopathogenesis during reinfection. A reduced viral load and downregulation of IL-4R on Th2 cells were observed in IFN-
-treated neonatal mice, suggesting dual mechanisms of action.
IMPORTANCE
Respiratory syncytial virus (RSV) is the most significant cause of lower respiratory tract infection in infancy worldwide. Despite
the dire need, we have failed to produce efficacious RSV vaccines or therapeutics. Part of the reason for this failure is our lack of
understanding of how RSV interacts with the infant immune system to suppress the development of protective immunity. In the
study described in the present paper, we used a neonatal mouse model, which more closely mimics human infants, to study the
role of the innate immune system, particularly type I interferons (IFNs) and plasmacytoid dendritic cells (pDCs), in the patho-
genesis of RSV infection. RSV infection in neonates induced limited type I IFN and pDC responses. IFN- treatment or adoptive
transfer of adult pDCs capable of producing IFN- prior to neonatal RSV infection decreased Th2-biased immunopathogenesis
during reinfection. These data suggest that IFN- is a promising target for future RSV vaccine design.
Respiratory syncytial virus (RSV) infection causes a significantglobal medical and economic burden. It is the number one
cause of bronchiolitis in infants, and every child is infected by RSV
by the age of 2 years. Moreover, a significant number of infants
who acquire severe disease from RSV infection develop asthma
that persists into adulthood (1). The annual medical cost due to
RSV infection in young children is estimated to exceed $600 mil-
lion (2). Insufficient knowledge of infant immunity was responsi-
ble for the failure of an RSV vaccine brought to clinical trials in the
1960s (3). This lack of knowledge, combined with the early use of
adult animal models to understand a disease in infants, is the main
reason that we lack an RSV vaccine today.
Our and other laboratories have therefore developed a neona-
tal mouse model that better mimics RSV disease in infants (4–9).
In this model, neonatal mice (7 days old) are infected with
RSV and various immunological parameters are measured. Nota-
bly, RSV-infected neonates mount limited Th1 (CD3, CD4, inter-
feron gamma-positive [IFN-], interleukin-4-negative [IL-4])
responses compared to the responses of their adult counterparts
(4). This observation is in line with the findings from postmortem
histological examinations of human infants who died of severe
RSV infections (10). Furthermore, when reinfected, mice initially
infected as neonates respond with larger numbers of Th2 (CD3,
CD4, IFN--negative [IFN-], IL-4-positive [IL-4]) (4, 6, 8,
9) and multifunctional Th (CD3, CD4, IFN-, IL-4) cells
(4), while the number of Th1 cells upon reinfection is equivalent
to that in mice initially infected as adults. This biased Th2 re-
sponse observed upon reinfection is associated with enhanced air-
way hyperreactivity (AHR), airway and lung eosinophilia, and
mucus hyperproduction (4, 6, 8, 9), all of which are consistent
with the observations for infants from the 1960s clinical trials who
died from community-acquired RSV infection (3).
The neonatal mouse model of RSV infection has proven to be
an invaluable model to study and understand RSV pathogenesis in
infants (5). Using this model, we have recently demonstrated that
interleukin 4 receptor  (IL-4R) on Th cells plays a pathogenic
role in RSV reinfection-associated immunopathophysiology (4).
We showed that neonatal Th cells (i.e., Th1 and Th2 cells) express
higher levels of IL-4R than adult Th cells. When Il4ra is specifi-
cally deleted from Th cells, all parameters of immunopathophysi-
ology associated with RSV reinfection are ablated or substantially
decreased in mice initially infected as neonates. Along with the
discovery of a role for IL-4R, other groups have demonstrated
that IL-13, a ligand for IL-4R, also plays a pathogenic role during
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reinfection in this neonatal mouse model (9). Human genetic
analysis, which demonstrates that certain IL-4R polymorphisms
(11) and IL-13/IL-4 haplotypes (12) are associated with severe
RSV infection, further corroborates these neonatal mouse data.
Though it is clear that the adaptive arm of the immune system
and its key molecules play vital roles in the immunopathogenesis
of RSV disease, adaptive immune responses are first instructed by
the innate response. Data generated from human primary cells
and adult animal models shed light on the innate immune re-
sponses to RSV. In particular, several laboratories have demon-
strated that type I IFNs (mainly IFN- and IFN-) and their ma-
jor producers, plasmacytoid dendritic cells (pDCs), are important
in protection from RSV disease. It has been reported that RSV
stimulates pDCs isolated from human peripheral blood mononu-
clear cells (13, 14) or murine bone marrow-derived pDCs (15, 16)
to produce type I IFNs ex vivo. Furthermore, several publications
have demonstrated that RSV infection of adult mice induces pul-
monary type I IFNs in vivo (17, 18) and that intranasal adminis-
tration of recombinant IFN- significantly reduces the lung viral
load, inflammation, weight loss, and clinical illness scores of RSV-
infected adult mice (19). It has also been demonstrated that RSV
infection induces recruitment of pDCs to the lungs of adult mice
and the depletion of pDCs results in an increased pulmonary viral
load and immunopathology (17).
Despite the apparent roles of type I IFNs and pDCs in deter-
mining RSV morbidity, there are few studies investigating type I
IFNs and pDCs in infants. Data demonstrate that pDCs are re-
cruited to the mucosal compartment of the airways and are readily
detectable in nasal washes from children infected with RSV (20);
however, there are very low levels of type I IFNs in nasal washes
from RSV-infected infants (21). Recent data from Stuart Turvey’s
group support these findings and demonstrate that pDCs isolated
from the cord blood of healthy term infants are unable to mount
robust type I IFN responses upon RSV infection ex vivo, unlike
pDCs from healthy adults, suggesting that human infant pDCs are
immature and/or less responsive at birth (22).
The present study is the first attempt, to our knowledge, to
characterize the role of type I IFN and pDC responses in immu-
nopathogenesis during RSV reinfection using a neonatal mouse
model. Our data demonstrate that neonatal mice mounted lim-
ited type I IFN and pDC responses during primary RSV infection.
Treatment of neonatal mice with IFN- or adoptive transfer of
adult pDCs prior to RSV infection significantly reduced the Th2-
biased immunopathophysiology, strongly suggesting that limited
type I IFN and pDC responses during infancy permit the develop-
ment of a Th2-biased immunopathophysiology in response to
RSV infection.
MATERIALS AND METHODS
Mice. BALB/c mice were purchased from Harlan Laboratories (Indianap-
olis, IN) and maintained in specific-pathogen-free facilities at the Louisi-
ana State University Health Sciences Center (LSUHSC; New Orleans, LA)
and the University of Tennessee Health Science Center (UTHSC; Mem-
phis, TN). Breeders were time mated, and pups born on the same date
were used for experiments. A set of pups was allowed to mature to 6 to 8
weeks of age and were then used as adult controls or the source of pDCs
for adoptive transfer studies.
All animal protocols were prepared in accordance with the Guide for
the Care and Use of Laboratory Animals (23) and approved by the Institu-
tional Animal Care and Use Committee at LSUHSC or UTHSC.
IFN- treatment. Mouse recombinant IFN-A was purchased from
PBL Interferon Source (Piscataway, NJ). At 16 h prior to RSV infection,
2  103 units (the dose extrapolated from the dosage used in adult mice
[17]) of IFN- was instilled intranasally into pups in 10 	l of phosphate-
buffered saline (PBS) containing 0.1% bovine serum albumin (BSA).
Control pups (pups treated with vehicle, here abbreviated NS) received 10
	l of PBS containing 0.1% BSA.
Purification of pDCs or CD11c cells and adoptive transfer. pDCs
were purified from adult spleens using OptiPrep gradient medium (Sigma-
Aldrich, St. Louis, MO) and a negative-selection kit from Miltenyi Biotec
Inc. (Auburn, CA). Briefly, a single-cell suspension of spleen cells was
prepared using a gentleMACS Octo dissociator and a spleen dissociation
kit. Spleen cells were then suspended in Hanks balanced salt solution
containing 15% OptiPrep density gradient medium and overlaid onto
11.5% OptiPrep and centrifuged. Low-density cells mostly consisting of
dendritic cells were collected and subjected to further purification for
pDCs using the negative-selection kit per the manufacturer’s instruction.
The purity of the pDCs isolated was verified by flow cytometry and was
above 85%. For adoptive transfer studies, pDCs were purified as described
above and suspended in 10 	l serum-free medium (SFM; SFM4MegaVir;
HyClone, Logan, UT), and 3  104 pDCs were intranasally instilled into
pups at 16 h prior to RSV infection. Control pups received 10 	l SFM.
CD11c cells were purified from adult spleens for adoptive transfer.
Adult splenocytes were isolated as described above, and CD11c cells
were selected using a positive-selection kit from Stemcell Technologies
(Vancouver, British Columbia, Canada). The purity of isolation was
above 90%. CD11c cells were suspended in 10 	l SFM, and 3  104 cells
were instilled intranasally into pups at 16 h prior to RSV infection. Con-
trol pups received 10 	l SFM.
RSV infection. Human RSV strain A2 (Advanced Biotechnologies
Inc., Columbia, MD) was propagated in and harvested from Vero cells
(ATCC, Manassas, VA) cultured in SFM and stored at 80°C until use.
Five-day-old pups or 6- to 8-week-old adults were infected intranasally
with RSV in SFM at a dose of 2  105 50% tissue culture infectious dose
(TCID50) per gram of body weight. Control mice received SFM.
Assessment of pulmonary viral load. At 4 days after the initial RSV
infection, lungs were isolated, weighed, and frozen until analysis by either
plaque assay (24) or real-time reverse transcription-PCR (RT-PCR)
methods (25). For plaque assays, supernatants from centrifuged lung ho-
mogenates were added onto Vero cells and overlaid with 0.3% agarose
(MP Biochemicals, Santa Ana, CA). Cells were incubated for 3 days, fixed
with 1% formaldehyde, and stained with 0.5% neutral red (Sigma-Al-
drich). The plaques were counted, and viral loads were expressed as the
number of PFU per gram of lung tissue.
For real-time PCR, RNA was isolated from frozen lungs using an
RNeasy plus minispace kit (Qiagen, Valencia, CA) per the manufacturer’s
instructions. Real-time RT-PCR was then performed using a SuperScript
III Platinum one-step quantitative RT-PCR (qRT-PCR) kit from Life
Technologies (Carlsbad, CA). The primers (25) used for the reaction were
NS1 forward primer (5=-CACAACAATGCCAGTGCTACAA-3=) and
NS1 reverse primer (5=-TTAGACCATTAGGTTGAGAGCAATGT-3=).
Cell staining and flow cytometry. To measure pDC levels in the lung,
single cells were isolated and labeled with a fixable viability dye and anti-
bodies to CD11c (N418) and PDCA-1 (eBio129c). Stained cells were then
assayed on a Canto II flow cytometer (BD Biosciences, Franklin Lakes,
NJ), and flow data were analyzed and plotted with FlowJo software (ver-
sion 7.6.5 for Windows; Tree Star, Ashland, OR). Single live cells were
gated before any further analysis. All buffers, viability dyes, and antibodies
were purchased from eBiosciences unless otherwise stated.
To determine the CD4 T cell populations in the lung, single cells were
isolated as described above and stimulated for 5 h in RPMI 1640 (Hy-
Clone) containing 10% heat-inactivated fetal bovine serum (FBS; Life
Technologies), 100 U/ml penicillin (HyClone), 100 mg/ml streptomycin
(HyClone), 5 ng/ml phorbol-12-myristate-13-acetate (PMA; Sigma-Al-
drich), and 500 ng/ml ionomycin (Sigma-Aldrich) in the presence of a
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protein transport inhibitor (1 	l/106 cells; GolgiPlug; BD Biosciences, Frank-
lin Lakes, NJ). After stimulation, the cells were stained with a fixable viability
dye, fixed, permeabilized, and labeled with antibodies to CD3 (17A2), CD4
(RM4-4; Biolegend), IFN- (XMG1.2), and IL-4 (BVD6-24G2). Flow data
were then acquired, analyzed, and plotted as described above.
Pulmonary function test. Airway resistance to methacholine (MeCh;
Sigma-Aldrich) challenge was measured using a Scireq FlexiVent system
(Montreal, QC, Canada). Briefly, mice were anesthetized, tracheoto-
mized, and ventilated, and the resistance of the airway was measured and
calculated. Raw data were normalized by subtracting the individual base-
line values obtained with 0 mg/ml MeCh, and these data were plotted as
normalized resistance.
Lung histopathology. Lungs were retroperfused to remove blood and
then gently inflated and fixed with zinc formalin (Thermo Fisher Scien-
tific). After fixation, tissue sections were prepared following standard pro-
cedures. Some slides were stained with hematoxylin-eosin (H&E) to iden-
tify cellular infiltrates. In particular, the eosinophils in the peribronchial
area of the lung specimens were quantified and expressed as the number of
eosinophils per surface area of the lung parenchyma. Other slides were
stained with periodic acid-Schiff (PAS) to quantify mucus production in
the airway epithelial cells. Images of randomly selected airways were ac-
quired and analyzed with ImageJ software, and mucus expression was
expressed as the number of mucus-positive cells per surface area of airway
epithelial cells.
BALF cellularity. Bronchoalveolar lavage fluid (BALF) was isolated in
1 ml of PBS containing 2% heat-inactivated FBS. BALF cells were counted,
centrifuged onto slides, stained with stain from a Hema-3 staining kit
(Thermo Fisher Scientific, Waltham, MA), and differentiated by two un-
biased observers using standard morphological criteria. Supernatants
were collected, snap-frozen, and stored at 80°C for cytokine analysis.
Cytokine measurement. Real-time PCR was performed to measure
the kinetics of IFN- expression in the lung. Total lung RNA was isolated
using a Quick-RNA MiniPrep kit from Zymo Research (Irvine, CA), and
then real-time RT-PCR was performed using a SuperScript III Platinum
one-step qRT-PCR kit (Life Technologies). The primers used for the re-
action were IFN-4 forward primer (5=-TGATGAGCTACTACTGGTCA
GC-3=) and IFN-4 reverse primer (5=-GATCTCTTAGCACAAGGATG
GC-3=).
To measure the protein levels of type I IFNs in the lung, total lung
proteins were isolated using the T-PER tissue protein extraction reagent
and quantified using the bicinchoninic acid protein assay reagent
(Thermo Fisher Scientific). The levels of IFN- and IFN- were then
measured using enzyme-linked immunosorbent assay (ELISA) kits per
the manufacturer’s instructions (PBL Interferon Source). The limit of
detection was 12.5 pg/ml for IFN- and 15.6 pg/ml for IFN-. All data
presented are above the limit of detection.
The levels of other cytokines in the BALF, including IFN-, IL-12
(p40), IL-4, and IL-13, were measured using a Milliplex mouse cytokine/
chemokine assay kit (Millipore Corporation, Billerica, MA) on a Bio-Plex
system (Bio-Rad Laboratories, Hercules, CA). Data outside the sensitivity
level of detection were excluded.
Statistics. Data were plotted as means 
 standard errors of the means
(SEMs) and analyzed using Prism (version 6) software (GraphPad Soft-
ware, La Jolla, CA). Student’s t test was used for all mouse studies except
for the pulmonary function test, data from which were analyzed by two-
way analysis of variance (ANOVA) and Bonferroni post hoc tests. Each
figure represents the results of one experiment, and every experiment
was repeated at least twice. Differences were considered significant if P was
0.05.
RESULTS
RSV infection induced limited type I IFN and pDC responses in
neonatal mouse lungs. Type I IFNs are important antiviral cyto-
kines induced during viral infections. We measured the amount of
type I IFNs in the lung at various time points after RSV infection.
Neonates were infected with RSV, and lungs were isolated at 5 h
postinfection and 1, 2, 4, and 6 days postinfection (dpi). The ex-
pression of IFN- was measured at these time points using real-
time RT-PCR. Although it has been reported that RSV A2 and
clinical strains are capable of inhibiting type I IFN expression in
human cells ex vivo (26), we observed induction of IFN- in the
lungs of RSV-infected mice as early as 5 h postinfection and a peak
in IFN- at 1 and 2 dpi (Fig. 1A). We further measured the protein
levels of type I IFNs, including both IFN- and IFN-, in the lung
homogenates of RSV-infected neonatal mice versus those in adult
mice. The level of IFN- was slightly, but significantly, increased
at 1 dpi in neonates (Fig. 1C; RSV-infected neonate versus sham-
infected neonate, 11.84 
 1.22 versus 5.57 
 0.57 ng/g lung pro-
tein), whereas the level of IFN- was not significantly different
from that in sham-infected neonates (Fig. 1B; RSV-infected neo-
nate versus sham-infected neonate, 5.51 
 0.51 versus 4.35 
 0.39
ng/g lung protein). More importantly, adults infected with RSV
induced significantly larger amounts of IFN- (Fig. 1B; RSV-in-
fected adult versus sham-infected adult, 76.16 
 5.59 versus
3.77 
 0.45 ng/g lung protein) and IFN- (Fig. 1C; RSV-infected
adult versus sham-infected adult, 42.25 
 2.92 versus 8.14 
 1.15
ng/g lung protein) than sham-infected adults at 1 dpi. The levels of
both IFN- and IFN- in RSV-infected adults were significantly
higher than those in RSV-infected neonates.
Numerous reports have shown that pDCs are a major source of
type I IFNs during viral infections (27, 28); we therefore compared
the kinetics of pDCs during RSV infection in neonatal versus adult
mice. Neonates or adults were infected with RSV, and the number
of pDCs in the lung was measured at 5 h postinfection and 7, 14,
and 21 dpi using flow cytometry (Fig. 2). RSV infection induced
the recruitment of pDCs to the lung, with levels peaking at 7 dpi
and declining to baseline levels by 21 dpi in both adults and neo-
nates (Fig. 2A and B). The frequency of pDCs was substantially
greater at 7 dpi in RSV-infected adults than sham-infected adults
(Fig. 2D; 6.16% 
 0.68% versus 0.33% 
 0.06%), whereas there
was only a slight, but significant, increase in the frequency of pDCs
from RSV-infected neonates compared to the frequency of pDCs
from sham-infected neonates (Fig. 2C; 0.38% 
 0.05% versus
0.26% 
 0.01%). Additionally, the frequency of pDCs was signif-
icantly greater at 7 dpi in adults infected with RSV (6.16% 

0.68%) than neonates infected with RSV (0.38% 
 0.05%). This ob-
servation is consistent with the data for type I IFN presented above,
and both results indicated that RSV infection in neonates induced
limited type I IFN and pDC responses in the lung.
IFN- treatment prior to neonatal RSV infection mitigated
AHR and lung pathology during reinfection. Both our laborato-
ries (4) and other groups (8, 9) have shown that mice initially
infected as neonates exhibit exacerbated AHR and lung pathology
during RSV reinfection compared to the AHR and lung pathology
exhibited by mice initially infected as adults; we therefore moni-
tored lung function and pathology following reinfection in mice
that were treated with IFN- prior to neonatal RSV infection.
Four-day-old pups were treated intranasally with 2  103 U (the
dose was extrapolated from the dosage used in adult mice [17]) of
IFN- or vehicle and then infected with RSV or serum-free me-
dium at 16 h posttreatment. These mice were then reinfected with
RSV at 4 weeks after primary infection, and AHR and lung pathol-
ogy were assessed at 6 days after reinfection (Fig. 3). Pulmonary
viral load data from other groups have shown that RSV infects and
replicates in the lung following reinfection (9).
Cormier et al.



























































As expected, the airway resistance to methacholine in mice
initially infected as neonates (mice treated with vehicle, infected as
neonates, and reinfected with RSV as adults [NS/RR mice]) was
significantly greater than that in sham-infected mice (mice treated
with vehicle and mock infected [NS/sham mice]) (Fig. 3A; 6.44 

0.83 versus 2.29 
 0.38 cm H2O · s/ml). IFN- treatment prior to
neonatal RSV infection substantially decreased AHR (for mice
treated with IFN-, infected as neonates, and reinfected with RSV
as adults [IFN-/RR mice] versus NS/RR mice, 3.86 
 0.81 versus
6.44 
 0.83 cm H2O · s/ml), while there was no significant differ-
ence in AHR between mice treated with IFN- prior to RSV in-
fection and mice treated with vehicle prior to sham infection
(IFN-/RR mice versus NS/sham mice, 3.86 
 0.81 versus 2.29 

0.38 cm H2O · s/ml). No difference in airway resistance was ob-
served between sham-infected mice treated with IFN- (IFN-/
sham mice) and vehicle (NS/sham mice) (2.50 
 0.51 versus 2.29 

0.38 cm H2O · s/ml).
Consistent with the lung function data, lung pathology dem-
onstrated that RSV reinfection induced moderate peribronchial
and perivascular inflammation in the lung, which was reduced
with IFN- treatment prior to RSV infection (Fig. 3B). In partic-
ular, a striking decrease in eosinophils was observed around the
airways of mice treated with IFN- compared to that in control
mice (IFN-/RR versus NS/RR mice, 1,095 
 185 versus 66 
 31
eosinophils/surface area of lung parenchyma). In addition, signif-
icantly fewer mucus-producing cells, indicated by positive PAS
staining, were detected in the lungs of mice treated with IFN-
than in the lungs of control mice (Fig. 3C and D; IFN-/RR versus
NS/RR mice, 0.40 
 0.02 versus 0.26 
 0.03 mucus-positive cells/
surface area of airway). Little to no inflammation or mucus pro-
duction was observed in mice treated with IFN- or vehicle and
sham infected (data not shown).
These data demonstrate a prophylactic effect of IFN- on RSV
infection in neonates that included significantly reduced AHR,
pulmonary inflammation, and mucus hyperproduction during
RSV reinfection.
IFN- treatment prior to neonatal RSV infection mitigated
Th2-biased responses during reinfection. Cellular immunologi-
cal analysis has previously revealed that the AHR and lung pathol-
ogy in mice initially infected as neonates are associated with biased
pulmonary Th2 responses (4). We therefore measured various
parameters of the Th cell immune response in the lung, including
pulmonary Th cell subsets, the cellularity of bronchoalveolar la-
vage fluid (BALF), and cytokine levels in BALF (Fig. 4).
Mice were treated and infected as described above, and lung
cells were isolated at 6 days after reinfection and stained for surface
markers (CD3 and CD4) and intracellular cytokines (IFN- and
IL-4). We have previously shown that mice initially infected as
neonates induce considerably more Th2 cells in the lung during
reinfection than mice initially infected as adults, while the level of
Th1 cells in the lung remains similar (hence, the response is Th2
biased) (4). Here, we confirmed that RSV reinfection of mice ini-
tially infected as neonates (NS/RR) induced high levels of Th1 cells
(CD3, CD4, IFN-, IL-4) and moderate levels of Th2 cells
FIG 1 RSV infection induced limited type I IFN responses in neonates. (A) Kinetics of IFN- in neonates. Five-day-old neonates were infected with RSV, and
the expression of IFNa4 was measured at various time points postinfection via real-time RT-PCR. The expression of IFN- relative to that of the Hprt
housekeeping gene is shown. Data are for 3 to 5 mice. (B and C) To compare the protein levels of type I IFNs, neonates or adults were infected with RSV or
medium, and the concentrations of IFN- and IFN- in lung homogenates at 1 dpi were measured using ELISA. (B) IFN- production in neonates and adults.
(C) IFN- production in neonates and adults. Data are for 3 to 4 mice. Individual data are shown as the mean 
 SEM. *, P  0.05.
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(CD3, CD4, IFN-, IL-4) and multifunctional Th cells
(CD3, CD4, IFN-, IL-4) in the lung (Fig. 4A). IFN- treat-
ment prior to neonatal RSV infection substantially reduced the level
of Th2 cells (for IFN-/RR versus NS/RR mice, 0.84% 
 0.16% ver-
sus 6.80% 
 1.66%) and multifunctional cells (2.15% 
 0.42% ver-
sus 9.39% 
 1.67%), while it maintained the level of Th1 cells
(46.96% 
 2.14% versus 42.94% 
 2.04%) (Fig. 4A and B).
As described in our previous publications (4, 6), RSV reinfection
FIG 2 RSV infection induced limited recruitment of pDCs to neonatal lungs. Five-day-old pups or adults were infected with RSV or sham infected, and the numbers
of pDCs in the lungs at various time points were measured using flow cytometry. (A) Kinetics of pulmonary pDCs expressed as the percentage of total lung cells; (B)
kinetics of pDCs expressed as total numbers of pDCs in the lungs; (C) representative flow plots for pDCs (CD11c, PDCA-1 positive) in neonates at 7 dpi; (D)
representative flow plots for pDCs in adults at 7 dpi. Data are for 4 mice. *, P  0.05 for RSV-infected versus sham-infected mice; #, P  0.05 for adults versus neonates.
Data are presented as the mean 
 SEM.
FIG 3 IFN- treatment prior to neonatal RSV infection attenuated AHR, inflammation, and mucus hyperproduction during RSV reinfection. Four-day-old pups were
treated with IFN- or vehicle. These mice were infected 16 h later, allowed to mature to adults, and reinfected with RSV at 4 weeks after initial infection. Airway
hyperactivity and lung pathology were assessed at 6 days after reinfection. (A) Airway resistance to methacholine. Data are for 5 to 6 mice. *, P  0.05. (B) Lung tissue
stained with H&E. Arrows, inflammatory cells. Magnification, 100. Bar  200 	m. (C) Lung tissue stained with PAS. Magenta staining indicates mucus. Arrows,
mucus-positive regions. Magnification, 100. (D) Enlarged images of selected regions in panel C. Magnification, 400. Bar  50 	m. NS/sham, mice treated with
vehicle and mock infected; IFN-/sham, mice treated with IFN- and mock infected; NS/RR, mice treated with vehicle, infected as neonates, and reinfected with RSV
as adults; IFN-/RR, mice treated with IFN-, infected as neonates, and reinfected with RSV as adults. Data are presented as the mean 
 SEM.
Cormier et al.



























































increased the levels of inflammatory cells in the BALF, including al-
veolar macrophages, lymphocytes, neutrophils, and eosinophils (Fig.
4C). Consistent with the reduced pulmonary inflammation (Fig.
3B), IFN- treatment prior to neonatal RSV infection signifi-
cantly decreased the total amount of inflammatory cells in the
BALF during reinfection compared to that in mice treated with
vehicle (for IFN-/RR versus NS/RR mice, 2.96  105 
 0.34 
105 versus 6.04  105 
 0.96  105 cells/ml). This decrease in total
inflammatory cells was mainly due to the decrease in eosinophils
(0.20  105 
 0.07  105 versus 1.92  105 
 0.32  105 cells/ml).
In line with the BALF cellularity and pulmonary Th profile, IFN-
treatment prior to neonatal RSV infection significantly reduced Th2
cytokine levels in BALF during reinfection, including both IL-4 and
IL-13 (Fig. 4D; for IFN-/RR versus NS/RR mice, 0.98 
 0.12 versus
9.88 
 1.42 pg/ml for IL-4 and 34.10 
 9.47 versus 137.93 
 15.1
pg/ml for IL-13). No difference in Th1 cytokines, including both
IFN- and IL-12, was observed between IFN-- and vehicle-treated
mice (82.79 
 19.31 versus 74.70 
 22.76 pg/ml for IFN- and
40.98 
 9.53 versus 37.00 
 9.12 pg/ml for IL-12).
Collectively, the pulmonary Th profile, BALF cellularity, and
cytokine levels described above demonstrate that IFN- treat-
ment prior to neonatal RSV infection decreased Th2-biased re-
sponses and reduced RSV pathogenesis upon reinfection.
Adoptive transfer of purified adult pDCs prior to neonatal
RSV infection induced pulmonary IFN- expression and allevi-
ated RSV reinfection-associated immunopathophysiology. As
demonstrated above, RSV infection induced limited pDC and
type I IFN responses in the neonatal lung. Additionally, IFN-
treatment prior to neonatal RSV infection reduced the typical Th2
immunopathophysiology during reinfection. Because pDCs are
the major source of type I IFNs (28), we hypothesized that adoptive
transfer of adult pDCs prior to neonatal RSV infection would also
reduce the Th2 immunopathophysiology during reinfection. Four-
day-old pups received 3  104 adult pDCs instilled intranasally. The
number of pDCs instilled was roughly the number of pulmonary
pDCs observed in adult naive mice. Because it is extraordinarily dif-
ficult to isolate this number of pDCs from neonates, control pups
received vehicle (serum-free medium [SFM]). Pups were infected
with RSV at 16 h after adoptive transfer and reinfected at 4 weeks after
initial infection. Various endpoints were measured at 6 days after
reinfection, including AHR, BALF cellularity, and the pulmonary Th
profile (Fig. 5). A set of pups was used to measure IFN-expression in
the lung at 1 dpi.
Because pDCs are the major source of type I IFNs during viral
infections, we measured the expression of IFN- in lung homog-
enates at 1 dpi in pups receiving adult pDCs or vehicle. As shown
in Fig. 5A, pups receiving adult pDCs exhibited a 6-fold induction
of IFN- in the lungs compared to that in the mice receiving
vehicle.
RSV reinfection induced AHR in mice initially infected as ne-
onates (Fig. 5B; for mice receiving SFM, infected as neonates, and
reinfected with RSV as adults [SFM/RR mice] versus mice receiv-
ing SFM and mock infected [SFM/sham mice], 6.60 
 1.01 versus
1.62 
 0.15 cm H2O · s/ml). Adoptive transfer of adult pDCs to the
lung prior to neonatal RSV infection significantly reduced AHR
compared to that in control mice (for mice receiving pDCs, in-
fected as neonates, and reinfected with RSV as adults [pDC/RR
mice] versus SFM/RR mice, 4.80 
 1.03 versus 6.60 
 1.01 cm
H2O · s/ml), and the airway resistance in mice receiving adult
pDCs was no different from that in mice receiving vehicle and
FIG 4 IFN- treatment prior to neonatal RSV infection mitigated the Th2-biased responses during reinfection. Four-day-old pups were treated with IFN- or
vehicle. These mice were infected 16 h later, allowed to mature to adults, and reinfected with RSV at 4 weeks after initial infection. Pulmonary T helper cell profiles
and BALF cellularity and cytokine levels were measured at 6 dpi. (A) Pulmonary Th profile. Data are for 4 to 5 mice. *, P  0.05. (B) Representative flow plot of
Th cells from mice treated with IFN- or vehicle and infected with RSV. (C) BALF cellularity. Data are for 5 to 6 mice. *, P  0.05. (D) BALF cytokine levels. Data
are for 3 to 5 mice. *, P  0.05. NS/sham, mice treated with vehicle and mock infected; IFN-/sham, mice treated with IFN- and mock infected; NS/RR, mice
treated with vehicle, infected as neonates, and reinfected with RSV as adults; IFN-/RR, mice treated with IFN-, infected as neonates, and reinfected with RSV
as adults. Data are presented as the mean 
 SEM.
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sham infected (for mice receiving pDCs and mock infected [pDC/
sham mice] versus SFM/sham mice, 1.45 
 0.14 versus 1.62 

0.15 cm H2O · s/ml).
Analysis of BALF cellularity demonstrated significant reduc-
tions in the number of alveolar macrophages (0.56  105 
 0.09 
105 versus 0.97  105 
 0.09  105 cells/ml), neutrophils (0.51 

0.18 versus 1.14 
 0.22 cells/ml), and, in particular, eosinophils
(0.07 
 0.03 versus 0.43 
 0.16 cells/ml) during reinfection in the
airways of mice receiving adult pDCs and infected with RSV as
neonates (pDC/RR mice) compared to the number in control
mice receiving vehicle (SFM/RR mice) (Fig. 5C). The total num-
bers of inflammatory cells and lymphocytes remained comparable
between pDC/RR and SFM/RR mice. In addition, mice receiving
adult pDCs prior to neonatal RSV infection (pDC/RR mice) re-
cruited fewer Th2 cells (1.31% 
 0.22% versus 3.50% 
 0.69%) and
multifunctional Th cells (5.05% 
 0.33% versus 9.54% 
 2.13%)
and more Th1 cells (57.78% 
 2.11% versus 49.02% 
 1.59%) than
mice receiving vehicle (SFM/RR mice) (Fig. 5D and E).
In order to exclude the possibility that the effects that we ob-
served were due to the adoptive transfer of any type of cells into the
neonatal lung, the above-described experiment was repeated with
3  104 CD11c cells purified from adult spleens, and the Th cell
profile during reinfection was analyzed. As shown in Fig. 5F, no
difference in any Th cell subset was observed between the mice
receiving vehicle and those receiving CD11c cells.
Collectively, these data show that adoptive transfer of purified
pDCs into the lungs prior to neonatal RSV infection decreased
AHR, airway inflammation and eosinophilia, and pulmonary
Th2-biased immune responses during RSV reinfection.
IFN- treatment or adoptive transfer of pDCs prior to neo-
natal RSV infection reduced the pulmonary viral load during
primary infection. Both IFN- treatment and adoptive transfer of
FIG 5 Adoptive transfer of adult pDCs prior to neonatal RSV infection induced pulmonary IFN- expression and attenuated the Th2-biased immunopathol-
ogies during RSV reinfection. Four-day-old pups received adult pDCs (A to E), CD11c cells (F), or serum-free medium (SFM) (A to F) at 16 h before initial RSV
infection. After 4 weeks, these mice were reinfected with RSV, and airway resistance, BALF cellularity, and Th cell profiles were measured at 6 days after
reinfection. (A) Relative IFN- expression in the lung homogenates at 1 dpi. Data are for 5 mice. *, P  0.05. (B) Airway resistance to methacholine. Data are for
4 to 5 mice. *, P  0.05. (C) BALF cellularity. Data are for 4 to 5 mice. *, P  0.05. (D) Pulmonary Th profile. Data are for 4 to 6 mice. *, P  0.05. (E)
Representative flow plot of the data in panel D. (F) Pulmonary Th profile in mice receiving CD11c cells or SFM. Data are for 5 mice. SFM/RSV, pups receiving
SFM and infected with RSV; pDC/RSV, pups receiving adult pDCs and infected with RSV; SFM/sham, mice receiving SFM and mock infected; pDC/sham, mice
receiving pDCs and mock infected; SFM/RR, mice receiving SFM, infected as neonates, and reinfected with RSV as adults; pDC/RR, mice receiving pDCs,
infected as neonates, and reinfected with RSV as adults; CD11c/RR, mice receiving CD11c cells, infected as neonates, and reinfected with RSV as adults. Data
are presented as the mean 
 SEM.
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adult pDCs prior to neonatal RSV infection decreased the Th2-
associated immunohistopathology during reinfection. Because
IFN- is an important antiviral cytokine and is produced mainly
by pDCs (28), we hypothesized that IFN- treatment or adoptive
transfer of pDCs prior to RSV infection reduces the pulmonary
viral load. Four-day-old pups were intranasally instilled with 2 
103 U of IFN-, 3  104 pDCs, or vehicle. At 16 h after instillation,
these mice were infected with RSV and lungs were isolated at 4 dpi
for virus quantification using both plaque assays and real-time
RT-PCR (Fig. 6).
Plaque assays demonstrated that IFN- treatment consider-
ably reduced the live RSV titer from 280 
 43 to 91 
 15 PFU/g of
lung (Fig. 6A). Consistent with the plaque assay data, real-time
RT-PCR data demonstrated a 96% reduction in the relative ex-
pression of the NS1 gene in mice pretreated with IFN- compared
to that in control mice receiving vehicle (Fig. 6B). The adoptive
transfer of pDCs prior to RSV infection similarly resulted in a
moderate, but significant, reduction in the pulmonary viral load,
as evidenced by a decrease in the live RSV titer from 280 
 43 to
172 
 28 PFU/g of lung and a 66% reduction in the relative ex-
pression of the NS1 gene compared to that in the mice receiving
vehicle.
IFN- treatment prior to neonatal RSV infection reduced
the T helper cell response during primary infection. As men-
tioned above, we and other groups have shown that the hallmark
of the immunopathophysiology during reinfection in mice ini-
tially infected as neonates is the biased Th2 responses following
reinfection in the adult. Because IFN- treatment prior to neona-
tal RSV infection reduced these Th2-biased responses to RSV
upon reinfection, we sought to determine if IFN- treatment also
changed the Th profile in the lung during primary infection (Fig.
7). Four-day-old pups were instilled with IFN- prior to RSV
infection. The Th profile was measured in the lung at 6 dpi using
flow cytometry.
Neonatal RSV infection induced the recruitment of Th1 cells,
Th2 cells, and multifunctional Th cells in the lungs (Fig. 7A and
B). Treatment with IFN- prior to RSV infection reduced all of
these Th cell subsets. Th1 cells declined from 0.49% 
 0.05% to
0.34% 
 0.032%, Th2 cells decreased from 0.057% 
 0.006% to
0.027% 
 0.005%, and multifunctional Th cells decreased from
0.006% 
 0.001% to 0.001% 
 0.0003% of CD4 T cells. In fact,
the levels of these three Th cell subsets decreased to homeostatic
baseline levels, as observed in the sham-infected mice (NS/sham
or IFN-/sham mice), despite the fact that live virus was detected
in the lungs of IFN--treated and RSV-infected mice (Fig. 6).
Importantly, we have recently shown that IL-4R expression
on T helper cells plays a central pathogenic role in the Th2-biased
responses of mice initially infected as neonates (4); we therefore
measured the level of IL-4R on Th cells during initial RSV infec-
tion. Mice were treated with IFN- prior to RSV infection, and the
IL-4R levels on pulmonary CD4 T cells were measured at 2 dpi,
as previously published (4). Consistent with our previous findings
(4), RSV infection in neonates did not change the expression of
IL-4R on CD4 T, Th1, or Th2 cells (Fig. 7C to E). Treatment
with IFN- significantly reduced the expression of IL-4R on Th2
cells. No significant decrease in expression of IL-4R on Th1 cells
was observed between IFN-- and vehicle-treated mice (mice
treated with IFN- and infected with RSV [IFN-/RSV mice] and
mice treated with vehicle and infected with RSV [NS/RSV mice])
or between IFN-/RSV mice and NS/sham or IFN-/sham mice.
Collectively, the data presented above demonstrate that IFN-
treatment prior to neonatal RSV infection reduced pulmonary Th
cell responses and IL-4R expression on Th2 cells, while it de-
creased the viral load, suggesting dual mechanisms of action.
DISCUSSION
Despite nearly 60 years of intense research on RSV, we still have no
efficacious vaccines or therapeutics for this virus. The initial use of
adult instead of neonatal animal models and the lack of knowledge
of immune responses in infants are partially responsible for the
slow progress. In fact, mice initially infected as neonates develop
biased Th2 pulmonary immune responses upon reinfection with
RSV, whereas mice initially infected as adults develop dominant
Th1 responses upon reinfection with RSV. In the present study, we
investigated the role of pDCs and type I IFNs in the pathogenesis
of RSV using our neonatal mouse model. We showed that primary
RSV infection in neonatal mice induced limited pDC and type I
IFN responses compared to the responses seen in adult mice. We
further demonstrated that intranasal instillation of recombinant
IFN- or the adoptive transfer of adult pDCs to the lungs prior to
neonatal RSV infection considerably decreased the immuno-
pathophysiology during RSV reinfection, including reducing
AHR, eosinophilia, mucus hyperproduction, and pulmonary Th2
responses. These data suggest that the limited pDC and type I IFN
responses in neonates during primary infection permit the Th2-
biased immunopathogenesis during RSV reinfection.
FIG 6 IFN- treatment or adoptive transfer of pDCs decreased the pulmonary viral load during primary RSV infection. Four-day-old pups were treated with
IFN- or vehicle or received pDCs at 16 h prior to RSV infection. At 4 dpi, lungs were isolated and viral loads were measured in lung homogenates by plaque assay
or real-time RT-PCR. (A) Plaque assay. Data are for 12 to 15 mice. *, P  0.05. (B) Relative expression of the NS1 gene. Threshold cycle values were normalized
to those for the Hprt housekeeping gene and then compared to those for NS/RSV mice. Data are for 4 to 5 mice. *, P  0.05. NS/RSV, mice treated with vehicle
and infected with RSV; pDC/RSV, mice receiving pDCs and infected with RSV; IFN-/RSV, mice treated with IFN- and infected with RSV. Individual data are
shown as the mean 
 SEM.
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Although both prophylactic IFN- treatment and adoptive
transfer of adult pDCs exerted similar immunomodulatory effects
during RSV reinfection, there were differences in the extent of the
effects between the two treatments that cannot be explained by the
differences in the antiviral properties of IFN- and pDCs (i.e.,
pDC transfer had less of an effect on viral load than IFN- treat-
ment). These differences include the following: (i) IFN- treat-
ment decreased the number of eosinophils and had no effect on
other cell types in the BALF during reinfection, whereas adoptive
transfer of pDCs decreased the number of eosinophils, mono-
cytes, and neutrophils (Fig. 4C versus 5B); and (ii) IFN- treat-
ment decreased pulmonary Th2 cells but had no effect on the
number of Th1 cells during reinfection, whereas adoptive transfer
of pDCs decreased the number of Th2 cells and increased the
number of Th1 cells in the lung (Fig. 4A versus 5C). Although
these differences were not tested in this study and were outside the
scope of this study, they might be due to properties other than the
antiviral effect of pDCs. For example, in addition to producing
IFN- upon viral infection, pDCs have been shown to acquire
dendrites, upregulate major histocompatibility complex class II
and costimulatory molecules, and activate naive T cells (29).
Therefore, adoptively transferred adult pDCs might serve not only
as a source of IFN- but also as additional antigen-presenting cells
driving the immune response toward the Th1 arm. Interestingly,
adoptive transfer of adult pDCs prior to RSV infection in the
neonate appeared to be less protective during the initial infection
(i.e., the pulmonary viral load was higher) and less beneficial dur-
ing reinfection (i.e., AHR was increased) than administration of
IFN-. This phenomenon may be because the number of trans-
ferred pDCs was insufficient to overcome the neonatal immune
microenvironment of the lung.
The mechanisms via which IFN- treatment mitigated the
Th2-biased immunopathologies during RSV reinfection in mice
initially infected as neonates appear to be multifactorial. The data
presented here clearly demonstrate that administration of IFN-
reduced the pulmonary viral load during primary infection in the
neonate and the Th2 bias during reinfection in the adult. The
reduction in viral load undoubtedly accounts for some improve-
ment in RSV-mediated disease. Although it is difficult to dissoci-
ate the antiviral effects of IFN-, our previous study clearly dem-
onstrated that enhanced IL-4R expression on neonatal Th cells
compared to that on adult Th cells plays a significant role in the
development of the Th2-biased immunopathologies following
RSV reinfection (4). Furthermore, the reduction of IL-4R on
Th2 cells during primary infection prevents Th2 bias, airway hy-
perreactivity, mucus hyperproduction, and inflammation upon
reinfection without affecting the viral load (6). In line with this
observation, the data presented here demonstrate that IFN-
treatment prior to RSV infection reduces the expression of IL-4R
on Th2 cells (Fig. 7C to E). Because IL-4R levels are higher in
neonates, where viral loads are lower than those in adults (30), and
do not change in response to RSV infection (4), we also propose
that the immunomodulatory aspects of IFN- play a role in the
effects observed here. Thus, we believe that both of the mecha-
nisms of IFN- action outlined above are involved in the observed
protective effect.
Although the IFN--induced downregulation of IL-4R was
moderate during primary infection, the outcome on disease fol-
FIG 7 IFN- treatment reduced Th responses to primary RSV infection in neonates. Four-day-old pups were treated with IFN- or vehicle at 16 h prior to RSV
infection. The pulmonary T cell profile or IL-4R expression on Th cells was measured at 6 dpi or 2 dpi, respectively. (A) Pulmonary Th profile at 6 dpi. Data are
for 5 to 8 mice. *, P  0.05. Data are presented as the mean 
 SEM. (B) Representative flow plots of the Th profile. (C) Relative expression of IL-4R on CD4
T cells. (D) Relative expression of IL-4R on Th1 cells. (E) Relative expression of IL-4R on Th2 cells. Data are for 9 to 12 mice. *, P  0.05. MFI, mean
fluorescence intensity; NS/sham, mice treated with vehicle and mock infected; IFN-/sham, mice treated with IFN- and mock infected; NS/RSV, mice treated
with vehicle and infected with RSV; IFN-/RSV, mice treated with IFN- and infected with RSV. Individual data are shown as the mean 
 SEM.
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lowing reinfection was substantial (i.e., airway function was im-
proved, and pulmonary inflammation, mucus hyperproduction,
and the Th2-biased response were dramatically reduced). In fact,
these results were strikingly similar to those that we previously
obtained with antisense oligonucleotides to IL-4R: the moderate
downregulation of IL-4R during neonatal RSV infection com-
pletely abolished reinfection-associated airway hyperactivity and
significantly decreased Th2-biased responses (6). We believe this
phenomenon to be due to fine-tuning of IL-4R signaling, which
results in a rebalancing of the immune response so that Th2 cells
no longer skew the immune response. This is evidenced by the
primary Th response, in which the ratio of Th1/Th2 is increased in
IFN--treated mice (for IFN-/RSV versus NS/RSV mice, 9.230 

8.230 versus 5.137 
 4.137).
In addition to its antiviral effects, IFN- has also been shown to
promote Th1 responses (31) and suppress Th2 responses (32) ex
vivo. As expected in our model (Fig. 7A and B), IFN- treatment
prior to neonatal RSV infection significantly decreased the num-
ber of pulmonary Th2 cells. Surprisingly, the number of pulmo-
nary Th1 cells was reduced in IFN--treated neonates following
RSV infection. Most importantly, the Th cell responses to RSV in
IFN--treated neonatal mice were reduced to the same level as
those in sham-infected animals, yet these diminished initial re-
sponses remained adequate to promote strong Th1 and substan-
tially reduced Th2 responses upon reinfection. The reason for the
decrease in pulmonary Th1 cells following RSV infection in the
neonate treated with IFN- and the strong Th1 response upon
reinfection is unclear (Fig. 6). We cannot exclude the possibility
that the reduction in the pulmonary viral load is responsible for
the decrease in pulmonary Th1 cells in IFN--treated, RSV-in-
fected neonates, but our data presented here demonstrating that
IFN- modulates IL-4R levels during initial infection and our
prior data (6) demonstrating that modulating IL-4R levels at the
time of initial infection changes immune responses in the neonate
suggest that IFN- also modulates the Th1/Th2 balance. Thus, we
believe that our data support two mechanisms of IFN- activity
on reducing RSV-mediated disease: (i) it reduces the viral load,
and (ii) it modulates immune responses through IL-4R. We feel
that our data are instructive for RSV vaccine design and suggest
that an adjuvant capable of inducing IFN- responses would offer
an additional benefit due to its ability to modulate the neonatal
immune response.
There were early attempts in the late 1980s and early 1990s to
test the feasibility of IFN- as an RSV therapeutic. Unfortunately,
the clinical trial showed that daily intramuscular injection of
IFN- into RSV-infected infants for three consecutive days did
not change the overall clinical course, the duration of oxygen re-
quirement, or viral shedding, although the treatment did induce a
more rapid drop in the clinical score during the first 3 days (33).
The difference between these human studies and our data in neo-
nates may be explained by the different strategies that we em-
ployed. First, in our model, IFN- was instilled directly onto the
mucosal surface, where RSV infection naturally occurs, whereas in
the human studies, IFN- was administered systemically. Second,
in our model, IFN- was instilled prior to RSV infection, with the
hope of preventing Th2-biased responses during reinfection,
whereas in the human studies, IFN- was administered as a ther-
apy after RSV infection. One very important result of this human
study is that it demonstrated that the use of IFN- in infants is safe
(34). In fact, RSV-infected infants ranging from 2 to 8 months old
received daily maximal doses of 70,000 U of IFN- per kg of body
weight with no toxicity being observed. One of the most intimi-
dating difficulties in RSV vaccine or therapeutic research is that
RSV is an infant disease, and any intervention for infants must be
applied with considerable forethought and extreme caution. We
feel that the safety of IFN- in human infants and the encouraging
results from our studies strongly suggest that IFN- is a promising
target for future RSV vaccine design due to its immunomodula-
tory property.
In summary, limited type I IFN and pDC responses in neonatal
mice permit the development of Th2-biased immunopathogen-
esis during RSV reinfection. IFN- treatment or adoptive transfer
of adult pDCs prior to neonatal RSV infection reduced the Th2-
biased immunopathophysiologies, possibly because of their anti-
viral properties and because they downregulated IL-4R expres-
sion on Th2 cells. These observations support using an adjuvant
capable of inducing IFN- in future RSV vaccine strategies.
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